BridgeBio Corporate Presentation 2024

BridgeBio is a biopharmaceutical company focused on developing medicines for rare diseases. The company highlights its progress with 2 FDA approvals, 6 potential approvals in its first 10 years, and 30+ clinical programs initiated. Key programs include fosdenopterin for molybdenum cofactor deficiency, acoramidis, infigratinib, and encaleret.